John Overdeck’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-45,316
| Closed | -$67K | – | 3005 |
|
|
2022
Q2 | $67K | Sell |
45,316
-1,070,200
| -96% | -$786K | ﹤0.01% | 2319 |
|
|
2022
Q1 | $1.28M | Buy |
1,115,516
+92,889
| +9% | +$151K | ﹤0.01% | 1579 |
|
|
2021
Q4 | $2.56M | Buy |
1,022,627
+1,010,627
| +8,422% | +$3.97M | 0.01% | 1716 |
|
|
2021
Q3 | $61K | Buy |
+12,000
| New | +$72.9K | ﹤0.01% | 4136 |
|
|
2021
Q2 | – | Sell |
-356,702
| Closed | -$3.11M | – | 4753 |
|
|
2021
Q1 | $3.11M | Buy |
+356,702
| New | +$3.69M | 0.01% | 1365 |
|
|
2020
Q4 | – | Sell |
-71,909
| Closed | -$858K | – | 3901 |
|
|
2020
Q3 | $858K | Buy |
71,909
+15,181
| +27% | +$203K | ﹤0.01% | 1864 |
|
|
2020
Q2 | $911K | Sell |
56,728
-14,496
| -20% | -$253K | ﹤0.01% | 1591 |
|
|
2020
Q1 | $1.1M | Buy |
+71,224
| New | +$1.53M | 0.01% | 1335 |
|
|
2019
Q4 | – | Sell |
-32,454
| Closed | -$335K | – | 4090 |
|
|
2019
Q3 | $335K | Sell |
32,454
-5,479
| -14% | -$69.1K | ﹤0.01% | 2887 |
|
|
2019
Q2 | $476K | Sell |
37,933
-28,831
| -43% | -$371K | ﹤0.01% | 2532 |
|
|
2019
Q1 | $827K | Sell |
66,764
-203,449
| -75% | -$2.27M | ﹤0.01% | 1944 |
|
|
2018
Q4 | $1.67M | Buy |
270,213
+228,192
| +543% | +$1.74M | 0.01% | 1341 |
|
|
2018
Q3 | $445K | Buy |
42,021
+30,284
| +258% | +$346K | ﹤0.01% | 2535 |
|
|
2018
Q2 | $159K | Buy |
+11,737
| New | +$183K | ﹤0.01% | 3168 |
|
Other funds holding EPZM
John Overdeck's EPZM Position: Q3 2022 in Review
John Overdeck sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 45,316 shares — an estimated $67K sold.
John Overdeck first reported a position in EPZM in Q2 2018 and held it in 14 quarters. The position peaked at $3.11M in Q1 2021. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- John Overdeck reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- John Overdeck sold 45,316 Epizyme, Inc shares in Q3 2022, an estimated $67K.
- John Overdeck first reported a position in Epizyme, Inc in Q2 2018 and held it in 14 quarters.
- John Overdeck's Epizyme, Inc position peaked at $3.11M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on Two Sigma Investments's 13F filing for Q3 2022, filed 14 Nov 2022.